Skip to content
Twitter page opens in new windowLinkedin page opens in new windowInstagram page opens in new window
info@pharmaust.com+61 8 9202 6814
PharmAust (PAA)
PharmAust (PAA)
  • HOME
  • ABOUT
    • Company Overview
    • Management Team
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL and Veterinary Trials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
  • INVESTOR CENTRE
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT
  • HOME
  • ABOUT
    • Company Overview
    • Management Team
    • Board
    • Corporate Directory
  • PIPELINE & TRIALS
    • Therapeutic Pipeline
    • MPL and Veterinary Trials
    • MPL and Human Trials
    • Publications
    • Pet Cancer Information Service
  • INVESTOR CENTRE
    • News & Announcements
    • Company Research
    • Financial Reports
    • Annual Reports
    • Investor Presentations
    • Corporate Governance
    • Top 20 Shareholders
  • MEDIA
    • Dr Richard Mollard – Full Interview Ticker TV – 17th June 2020
    • Interview with TechInvest – May 2020
    • Dr. Richard Mollard – 6IX Interview March 2020
    • PharmAust In the News
    • PharmAust Videos
    • PharmAust New Cancer Treatment
    • PharmAust and Catalent Commence GMP Tablet Manufacture (Audio)
    • PharmAust on Youtube
  • CONTACT

Top 20 Shareholders

  • Top 20 Shareholders

December 31, Top 20 Shareholders

January 4, 2021

November 30, Top 20 Shareholders

December 1, 2020

October 31, Top 20 Shareholders

November 2, 2020

September 30, Top 20 Shareholders

October 1, 2020

August 31, Top 20 Shareholders

September 1, 2020

July 31, Top 20 Shareholders

August 1, 2020

June 30, Top 20 Shareholders

July 1, 2020

May 31, Top 20 Shareholders

June 1, 2020

April 30, Top 20 Shareholders

April 30, 2020

31 March, Top 20 Shareholders

March 31, 2020

29 February, Top 20 Shareholders

February 29, 2020

29 November, Top 20 Shareholders

December 2, 2019

30 August 2019 Top 20 Shareholders

September 2, 2019

31 July 2019 Top 20 Shareholders

July 31, 2019

Top 20 Shareholders, 5 July 2019

July 5, 2019

Top 20 Shareholders, 31 May 2019

June 3, 2019

30 April, Top 20 Shareholders

May 6, 2019

Top 20 Shareholders, March 2019

March 27, 2019

Top 20 Shareholders, March 1

March 1, 2019

Top 20 Shareholders January 2019

February 6, 2019

Top 20 Shareholders 30th December 2018

January 7, 2019

Top 20 Shareholders 31st October 2018

November 6, 2018

Top 20 Shareholders October 2018

October 5, 2018

Top 20 Shareholders September 2018

September 24, 2018

Top 20 Shareholders August 2018

August 17, 2018

Top 20 Shareholders July 2018

July 13, 2018

Top 20 Shareholders June 2018

June 10, 2018

Top 20 Shareholders April 2018

April 27, 2018

Top 20 Shareholders Feb 2018

February 26, 2018
MENU
  • Home
  • About Us
  • Pipeline & Trials
  • Investor Centre
  • Media
  • Contact Us
SUBSCRIBE TO OUR NEWSLETTER

TWITTER

PharmAustFollow

PharmAust
Retweet on TwitterPharmAust Retweeted
PharmAustPharmAust@PharmAust·
13 Jan

DOGS WITH CANCER NEEDED FOR FREE CLINICAL TRIAL

PharmAust is currently recruiting dogs with B cell lymphoma for a Phase IIb clinical trial with a non-toxic anti cancer drug

Pet owners interested in enrolling their dog need a referral from their vet to their nearest trial centre

Reply on Twitter 1349323220608978947Retweet on Twitter 134932322060897894711Like on Twitter 134932322060897894724Twitter 1349323220608978947
Load More...
Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions

Go to Top